Report      Database

    Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

    Date: 18 Jul, 2013              Type: Life Science              Pages: 164

    Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide
    • Electronic Access - Single User License
      $1,290.00
    • CD-ROM Mail Delivery
      $1,390.00
    • Hard-copy Mail Delivery
      $1,440.00
    • Electronic Access - Multi User License
      $2,090.00

    Hepatitis C Market Overview
     
    Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing, treatment and the prospect of increasing incidence associated with the epidemic of injection drug use. Hepatitis C is a leading cause of chronic liver disease, end-stage cirrhosis and liver cancer. Because of the slow progression and asymptomatic character of the infection, many people are unaware of having it. As a consequence, the infection is often diagnosed at a late stage when treatment options are limited. As no effective vaccine against the Hepatitis C virus (HCV) has been discovered so far the market is driven by therapeutics. The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the HCV market. The growth in HCV drugs market is primarily attributed to high unmet need in the market which is expected to be fulfilled by strong pipeline candidates. Low levels of awareness and knowledge about HCV have been identified as a formidable challenge to prevention and care.
     
    Renub Research study titled “Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 164 page report with 25 Figures and 2 Tables studies the Hepatitis C Drug Market Landscape. This report contains 7 chapters.
     
    A. Hepatitis C Drugs Market & Forecast (Chapter 2) 
    B. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3) 
    C. Hepatitis C Deals & Acquisitions (Chapter 4) 
    D. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter 5) 
    E. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter 6) 
    F. Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)
     
    Hepatitis C – Approved Drugs sales & Forecast Analysis (To 2016) (Chapter No. 3) 
     
    1. Pegasys 
    2. Pegintron 
    3. Incivek
    4. Victrelis
     
    Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter No. 5) 
     
    1. Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)
    2. Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim)
    3. Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)
    4. PEG-Interferon Lambda (Company: Bristol-Myers Squibb)
    5. Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)
    6. Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)
    7. BI-207127 (Company: Boerhinger Ingelheim)
    8. ABT-450/r (Ritonavir) (Company: Abbott Laboratories)
    9. ABT-267 (Company: Abbott Laboratories)
    10. ABT-072/333 (Company: Abbott Laboratories)
    11. Alisporivir (Company: Novartis)
     
    Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter No. 6) 
     
    1. Mericitabine (RG-7128) (Company: Roche)
    2. Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)
    3. GS-9256 (Company: Gilead Sciences)
    4. GS-9451 (Company: Gilead Sciences)
    5. MK-5172 (Company: Merck)
    6. Sovaprevir (ACH-1625) (Company: Achillion)
    7. IDX-320 (Company: Idenix)
    8. MK-8742 (Company: Merck)
    9. ACH-3102 (Company: Achillion Pharmaceuticals, Inc)
    10. IDX-719 (Company: Idenix)
    11. PPI-668 (Company: Presidio Pharmaceuticals)
    12. Setrobuvir (ANA-598) (Company: Roche)
    13. VX-222 (Company: Vertex Pharmaceuticals)
    14. GS-9669 (Company: Gilead Sciences)
    15. GS-9190 (Tegobuvir) (Company: Gilead Sciences)
    16. BMS-791325 (Company: Bristol-Myers Squibb)
     
    Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)
     
    1. Simeprevir (TMC 435) 
    2. Faldaprevir (BI 201335) (Boerhinger Ingelheim) 
    3. Asunaprevir (BMS-650032) 
    4. Sofosbuvir (PSI-7977 or GS-7977) 
    5. Daclatasvir (BMS-790052) 
    6. ABT-450/r (Ritonavir) 
    7. ABT-072/333 
    8. Alisporivir 
    9. Mericitabine (RG-7128)
    10. Danoprevir (RG7227) 
    11. GS-9256
    12. Setrobuvir (ANA-598) 
    13. VX-222 
    14. GS-9190 (Tegobuvir)
    15. BMS-791325
       
    Data Sources
     
    This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.
     
    Primary sources include industry surveys and telephone interviews with industry experts. 
     
    Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases. 

    1. Executive Summary

    2. Hepatitis C Drugs – Market & Forecast

    3. Hepatitis C – Approved Drugs Sales & Forecast
    3.1 Pegasys Sales and Forecast
    3.2 Pegintron Sales and Forecast
    3.3 Incivek Sales and Forecast
    3.4 Victrelis Sales and Forecast

    4. Hepatitis C – Deals & Acquisitions 

    5. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) 

    5.1 Simeprevir (TMC 435) (Company: Janssen Pharmaceutical) 
    5.1.1 Phase I
    5.1.2 Phase II
    5.1.3 Phase III

    5.2 Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim) 
    5.2.1 Phase I
    5.2.2 Phase II
    5.2.3 Phase III

    5.3 Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb) 
    5.3.1 Phase I
    5.3.2 Phase II
    5.3.3 Phase III

    5.4 Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences) 
    5.4.1 Phase II
    5.4.2 Phase III

    5.5 Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb) 
    5.5.1 Phase II
    5.5.2 Phase III

    5.6 BI-207127 (Company: Boerhinger Ingelheim) 
    5.6.1 Phase I
    5.6.2 Phase II
    5.6.3 Phase III

    5.7 PEG-Interferon Lambda (Company: Bristol-Myers Squibb) 
    5.7.1 Phase I
    5.7.2 Phase III

    5.8 ABT-450/r (Ritonavir) (Company: Abbott Laboratories) 
    5.8.1 Phase I
    5.8.2 Phase II
    5.8.3 Phase III

    5.9 ABT-267 (Company: Abbott Laboratories) 
    5.9.1 Phase II
    5.9.2 Phase III

    5.10 ABT-072/333 (Company: Abbott Laboratories) 
    5.10.1 Phase I
    5.10.2 Phase II
    5.10.3 Phase III

    5.11 Alisporivir (Company: Novartis) 
    5.11.1 Phase II
    5.11.2 Phase III

    6. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) 

    6.1 Mericitabine (RG-7128) (Company: Roche) 
    6.1.1 Phase II

    6.2 Danoprevir/r (Ritonavir) (RG7227) (Company: Roche) 
    6.2.1 Phase I
    6.2.2 Phase II

    6.3 GS-9256 (Company: Gilead Sciences) 
    6.3.1 Phase II

    6.4 GS-9451 (Company: Gilead Sciences) 
    6.4.1 Phase II

    6.5 MK-5172 (Company: Merck) 
    6.5.1 Phase I
    6.5.2 Phase II

    6.6 Sovaprevir (ACH-1625) (Company: Achillion) 
    6.6.1 Phase II

    6.7 IDX-320 (Company: Idenix) 
    6.7.1 Phase I

    6.8 MK-8742 (Company: Merck) 
    6.8.1 Phase I
    6.8.2 Phase II

    6.9 ACH-3102 (Company:  Achillion Pharmaceuticals, Inc) 
    6.9.1 Phase I
    6.9.2 Phase II

    6.10 IDX-719 (Company: Idenix) 
    6.10.1 Phase I
    6.10.2 Phase II

    6.11 PPI-668 (Company: Presidio Pharmaceuticals) 
    6.11.1 Phase I

    6.12 Setrobuvir (ANA-598) (Company: Roche) 
    6.12.1 Phase I
    6.12.2 Phase II

    6.13 VX-222 (Company: Vertex Pharmaceuticals) 
    6.13.1 Phase I
    6.13.2 Phase II

    6.14 GS-9669 (Company: Gilead Sciences ) 
    6.14.1 Phase I
    6.14.2 Phase II

    6.15 GS-9190 (Tegobuvir) (Company: Gilead Sciences) 
    6.15.1 Phase II

    6.16 BMS-791325 (Company: Bristol-Myers Squibb) 
    6.16.1 Phase II

    7. Hepatitis C - Pipeline Drugs Sales Forecast

    7.1 Simeprevir (TMC 435) Sales Forecast
    7.2 Faldaprevir (BI 201335) (Boerhinger Ingelheim) Sales Forecast
    7.3 Asunaprevir (BMS-650032) Sales Forecast
    7.4 Sofosbuvir (PSI-7977 or GS-7977) Sales Forecast
    7.5 Daclatasvir (BMS-790052) Sales Forecast
    7.6 ABT-450/r (Ritonavir) Sales Forecast
    7.7 ABT-072/333 Sales Forecast
    7.8 Alisporivir Sales Forecast
    7.9 Mericitabine (RG-7128) Sales Forecast
    7.10 Danoprevir (RG7227) Sales Forecast
    7.11 GS-9256 Sales Forecast
    7.12 Setrobuvir (ANA-598) Sales Forecast
    7.13 VX-222 Sales Forecast
    7.14 GS-9190 (Tegobuvir) Sales Forecast
    7.15 BMS-791325 Sales Forecast

    List of Figures: 

    Figure 2 1: Global – Hepatitis C Drug Market (Million US$), 2011 – 2012
    Figure 2 2: Global – Forecast for Hepatitis C Drug Market (Million US$), 2013 – 2018

    Figure 3 1: Global – Pegasys Sales (Million US$), 2005 – 2012
    Figure 3 2: Global – Forecast for Pegasys Sales (Million US$), 2013 – 2016
    Figure 3 3: Global – Pegintron Sales (Million US$), 2009 – 2012
    Figure 3 4: Global – Forecast for Pegintron Sales (Million US$), 2013 – 2016
    Figure 3 5: Global – Incivek Sales (Million US$), 2011 – 2012
    Figure 3 6: Global – Forecast for Incivek Sales (Million US$), 2013 – 2016
    Figure 3 7: Global – Victrelis Sales (Million US$), 2011 – 2012
    Figure 3 8: Global – Forecast for Victrelis Sales (Million US$), 2013 – 2016

    Figure 7 1: Global – Forecast for Simeprevir (TMC 435) Sales (Million US$), 2014 – 2018
    Figure 7 2: Global – Forecast for Faldaprevir (BI-201335) Sales (Million US$), 2014 – 2018
    Figure 7 3: Global – Forecast for Asunaprevir (BMS-650032) Sales (Million US$), 2015 – 2019
    Figure 7 4: Global – Forecast for Sofosbuvir (PSI-7977 or GS-7977) Sales (Million US$), 2014 – 2018
    Figure 7 5: Global – Forecast for Daclatasvir (BMS-790052) Sales (Million US$), 2015 – 2018
    Figure 7 6: Global – Forecast for ABT-450/r Sales (Million US$), 2016 – 2019
    Figure 7 7: Global – Forecast for ABT-072/333 Sales (Million US$), 2015 – 2019
    Figure 7 8: Global – Forecast for Alisporivir Sales (Million US$), 2014 – 2019
    Figure 7 9: Global – Forecast for Meracitabine (RG-7128) Sales (Million US$), 2015 – 2018
    Figure 7 10: Global – Forecast for Danoprevir Sales (Million US$), 2015 – 2018
    Figure 7 11: Global – Forecast for GS-9256 Sales (Million US$), 2015 – 2019
    Figure 7 12: Global – Forecast for Setrobuvir (ANA-598) Sales (Million US$), 2015 – 2018
    Figure 7 13: Global – Forecast for VX-222 Sales (Million US$), 2016 – 2018
    Figure 7 14: Global – Forecast for GS-9190 Sales (Million US$), 2015 – 2019
    Figure 7 15: Global – Forecast for BMS-791325 Sales (Million US$), 2015 – 2019

     

    List of Tables:


    Table 4 1: Hepatitis C – Deals & Acquisitions in the anti-HCV Drug Space, 2004 – 2012
    Table 5 1: Clinical Trial – ABT-450/r


    Related Products